Brought to you by 
Tribute acquires US rights to Sun's Fibricor
23 Jun 2015
Executive Summary
Tribute Pharmaceuticals Canada Inc. acquired US rights to Sun Pharmaceutical Industries Ltd.'s cholesterol treatment Fibricor (fenofibrate) and its authorized generic.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Tribute acquires US rights to Sun's Fibricor
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice